盐酸多柔比星脂质体注射液联合注射用紫杉醇（白蛋白结合型）致严重皮肤损害1例分析

doi:10.19803/j.1672-8629.2021.03.16

摘要/Abstract

摘要： 目的提醒临床医生在联合使用多柔比星脂质体和紫杉醇（白蛋白结合型）时应密切关注用药安全。方法分析了1例43岁女性患者联合使用多柔比星脂质体和紫杉醇（白蛋白结合型）后出现3级手足综合征和2级皮肤擦烂样皮炎的病例,文献回顾上述2种药物所致皮肤毒性的临床表现、发病机制和防治措施。结果该患者的手足综合征很可能由多柔比星脂质体引起,擦烂样皮炎很可能由多柔比星脂质体和紫杉醇（白蛋白结合型）共同引起,经过减量、延迟化疗以及中药等对症干预后,患者皮肤症状逐渐缓解。结论多柔比星脂质体和紫杉醇（白蛋白结合型）联用可能会引起严重的皮肤毒性,严重影响患者的生活质量,应引起临床医师重视,在使用过程中应加强对患者的宣教并积极做好防护措施。

关键词: 盐酸多柔比星脂质体注射液, 注射用紫杉醇（白蛋白结合型）, 手足综合征, 擦烂样皮炎, 药品不良反应

Abstract: Objective To remind clinicians to pay close attention to medication safety when doxorubicin liposomes and paclitaxel (albumin-bound type) are used in combination. Methods One case of a 43-year-old female patient with grade 3 hand-foot syndrome and grade 2 intertrigo-like eruption after combined use of doxorubicin liposome and paclitaxel (albumin-bound type) was analyzed. Literature about the clinical manifestations, pathogenesis and prevention of skin toxicity caused by the above two drugs was reviewed. Results The patient's hand-foot syndrome was probably caused by doxorubicin liposomes, and the intertrigo-like eruption by the combined use of doxorubicin liposomes and paclitaxel (albumin-bound). After such symptomatic interventions as dose reduction, delayed chemotherapy and traditional Chinese medicine, the patient' s skin symptoms were gradually relieved. Conclusion The combined use of doxorubicin liposomes and paclitaxel (albumin-bound type) may cause serious skin toxicity and impact the quality of life of patients, which deserves the attention of clinicians. Patients should be better informed of the related risk and take precautions.

Key words: doxorubicin liposome injection, paclitaxel (albumin-binding), hand-foot syndrome, intertrigo-like eruption, adverse drug reaction

中图分类号:

R944.11

周香珍, 李京泰, 任少琳, 张纯萍, 张天花. 盐酸多柔比星脂质体注射液联合注射用紫杉醇（白蛋白结合型）致严重皮肤损害1例分析[J]. 中国药物警戒, 2021, 18(3): 280-283.

ZHOU Xiangzhen, LI Jingtai, REN Shaolin, ZHANG Chunping, ZHANG Tianhua. One Case of Severe Skin Damage Induced by Combination of Doxorubicin Hydrochloride Liposome Injection and Paclitaxel for Injection (albumin-binding)[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 280-283.

参考文献

[1] Xie YL, Su H.Doxorubicin liposome[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2010, 18(2): 107-111.
[2] Xu JM, Xia XJ, Liu YL.Advances in clinical research of new formulation of paclitaxel[J]. Practical Pharmacy and Clinical Remedies(实用药物与临床), 2016, 19(4) : 510-517.
[3] Xu L, Liu YH.Breast cancer international guidelines and clinical practice in China[J]. Journal of Clinical Surgery(临床外科杂志), 2019, 27(3): 181-183.
[4] U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v4.0. (2009)[EB/OL]. (2009-05-28)[2019-07-26].https://www.researchgate.net/profile/Masayuki_Watanabe2/publication/263706737_An_original_scoring_system_for_predicting_postoperative_morbidity_after_esophagectomy_for_esophageal_cancer/links/560e5db508ae 48337515ee75. pdf.
[5] Michal L, Ayala H, Olga L, et al.Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin[J]. Arch Dermatol, 2000, 136(12): 1475-1480.
[6] Annette D, Mareike A, Florian S, et al.The hand-foot-syndrome associated with medical tumor therapy -classification and management[J]. Journal of the German Society of Dermatology, 2010, 8(9): 652-661.
[7] Lorussol D, Stefanol AD, Caronel V, et al.Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome)[J]. Annals of Oncology, 2007, 18(7): 1159-1164.
[8] Ranson MR, Carmichael J, O'Byrne K, et al. A Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial[J]. J Clin Oncol, 1997, 15(10): 3185-3191.
[9] Wang ML, Cheng HL, Wang FW, et al.A case report of doxorubicin liposomes causing abrasion-like dermatitis and literature review[J]. Journal of Fudan University (Medical Edition)(复旦学报(医学版)), 2016, 43(4): 502-504.
[10] Zong Yu, Wu JY, Shen KW, et al.Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and metaanalysis[J]. Oncotarget, 2017, 8(10): 17360-17372.
[11] Mizue F.Toxic erythema with eccrine squamous syringometaplasia induced by nanoparticle albumin-bound paclitaxel[J]. Journal of Dermatology, 2015, 42(11): 1134-1135.
[12] Yasutsuna S, Tomohiro N, Hirofumi Y, et al.Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer[J]. Cancer Science, 2014, 105(7): 812-817.
[13] Edwards SJ.Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer[J]. Semin Oncol Nurs, 2003, 19(3): 9-39.
[14] Mangili G, Petrone M, Gentile C, et al.Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling[J]. Gynecol Oncol, 2008, 108(2): 332-335.
[15] Drake RD, Lin WM, King M, et al.Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies[J]. Gynecol Oncol, 2004, 94(2): 320-324
[16] Zhou P, Zhu WF.Nursing observation of oral administration of vitamin B6 combined with external application of MEBO in treating hand-foot syndrome caused by liposomal adriamycin[J]. Digest of the World's Latest Medical Information(世界最新医学信息文摘), 2017, 17(82): 9-10.
[17] Chang R, Gu F, Geng JY.The effect of Kangfuxin liquid on the treatment of chemotherapy-related hand-foot syndrome and nursing countermeasures[J]. Integrated Traditional Chinese and Western Medicine Nursing(中西医结合护理), 2019, 5(3) : 162-164.
[18] Huang HF.Clinical study of Xijiao Dihuang Decoction in the treatment of hand-foot syndrome caused by capecitabine chemotherapy[J]. Jiangxi Traditional Chinese Medicine(江西中医), 2016, 47(8): 52-53.